Data for ST000664   

(Analysis AN001014): Average values per metabolite and experimental factor (Units:Peak area normalized)

Metabolite structureAll dataF1F2F3F4F5F6F7F8
CerP 21:0; [M-H]-@2.12
0.03 0.05 0.03 0.05
CL 66:1; [M-2H](2-)@6.32
0.23 0.21 0.36 0.17
CL 68:1; [M-2H](2-)@7.36
0.02 0.03 0.01 0.01
CL 70:1; [M-2H](2-)@6.53
0.13 0.10 0.18 0.15
CL 70:5; [M-2H](2-)@6.06
0.02 0.02 0.04 0.02
CL 72:1; [M-2H](2-)@7.76
0.01 0.03 0.01 0.02
CL 72:3; [M-2H](2-)@6.83
0.01 0.01 0.02 0.02
CL 72:7; [M-2H](2-)@6.14
0.11 0.10 0.12 0.12
CL 74:1; [M-2H](2-)@6.80
0.70 0.61 0.56 0.59
CL 74:3; [M-2H](2-)@5.64
0.00 0.00 0.00 0.00
CL 74:3; [M-2H](2-)@6.36
0.03 0.03 0.05 0.03
CL 74:5; [M-2H](2-)@6.46
0.23 0.17 0.37 0.22
CL 76:10; [M-2H](2-)@6.67
0.12 0.08 0.14 0.11
CL 76:12; [M-2H](2-)@6.67
0.01 0.01 0.01 0.01
CL 76:3; [M-2H](2-)@7.14
0.10 0.10 0.16 0.15
CL 76:6; [M-2H](2-)@6.67
0.01 0.01 0.01 0.01
CL 76:7; [M-2H](2-)@6.79
0.06 0.08 0.06 0.08
CL 76:8; [M-2H](2-)@6.86
0.02 0.01 0.03 0.04
CL 78:11; [M-2H](2-)@6.17
0.45 0.36 0.34 0.27
CL 78:3; [M-2H](2-)@7.08
0.18 0.10 0.23 0.16
CL 78:3; [M-2H](2-)@7.57
0.16 0.12 0.25 0.17
CL 78:4; [M-2H](2-)@7.08
0.04 0.05 0.06 0.06
CL 78:5; [M-2H](2-)@7.31
0.20 0.22 0.20 0.23
CL 78:7; [M-2H](2-)@6.71
1.16 1.08 1.13 1.51
CL 82:15; [M-2H](2-)@6.04
0.01 0.01 0.01 0.01
CL 82:9; [M-2H](2-)@6.39
0.02 0.02 0.02 0.01
CL 86:15; [M-2H](2-)@6.55
0.01 0.01 0.01 0.01
lysoPE 16:0; [M-H]-@1.76
0.12 0.12 0.12 0.12
lysoPE 16:1; [M-H]-@1.33
0.00 0.00 0.00 0.00
lysoPE 18:0; [M-H]-@2.56
0.15 0.17 0.13 0.17
lysoPE 18:1; [M-H]-@1.93
0.14 0.16 0.17 0.14
lysoPE 18:2; [M-H]-@1.45
0.08 0.08 0.10 0.09
lysoPE 20:3; [M-H]-@1.70
0.01 0.01 0.01 0.01
lysoPE 20:4; [M-H]-@1.42
0.08 0.08 0.08 0.09
lysoPE 20:5; [M-H]-@1.13
0.00 0.00 0.00 0.00
lysoPE 22:4; [M-H]-@1.96
0.11 0.08 0.12 0.08
lysoPE 22:5; [M-H]-@1.64
0.15 0.14 0.14 0.16
lysoPE 22:6; [M-H]-@1.36
0.07 0.08 0.05 0.08
PA 34:0; [M-H]-@7.68
0.07 0.11 0.06 0.08
PA 36:1; [M-H]-@6.81
0.01 0.01 0.01 0.01
PA 38:3; [M-H]-@7.02
0.70 1.09 0.95 1.11
PA 40:4; [M-H]-@6.87
0.05 0.07 0.07 0.11
PA 41:4; [M-H]-@6.57
0.17 0.19 0.20 0.16
PC 19:2; [M-Ac-H]-@1.43
0.07 0.14 0.10 0.09
PC 26:0; [M-Ac-H]-@4.59
0.00 0.00 0.00 0.00
PC 28:0; [M-Ac-H]-@5.36
0.54 0.60 0.93 0.59
PC 28:1; [M-Ac-H]-@4.81
0.05 0.04 0.05 0.05
PC 30:0; [M-Ac-H]-@6.06
0.08 0.07 0.09 0.08
PC 30:1; [M-Ac-H]-@5.52
0.92 0.88 0.78 0.56
PC 30:2; [M-Ac-H]-@5.00
0.03 0.02 0.06 0.03
PC 31:0; [M-Ac-H]-@6.32
0.01 0.01 0.01 0.01
PC 31:1; [M-Ac-H]-@5.86
0.01 0.01 0.00 0.00
PC 31:1; [M-Ac-H]-@6.55
0.15 0.12 0.14 0.16
PC 32:0; [M-Ac-H]-@6.69
0.58 0.60 0.61 0.56
PC 32:1; [M-Ac-H]-@6.18
0.23 0.23 0.22 0.14
PC 32:2; [M-Ac-H]-@5.70
0.28 0.24 0.40 0.21
PC 32:3; [M-Ac-H]-@5.26
0.03 0.02 0.04 0.01
PC 33:0; [M-Ac-H]-@7.07
0.03 0.04 0.03 0.03
PC 33:1; [M-Ac-H]-@6.64
0.17 0.16 0.19 0.14
PC 33:2; [M-Ac-H]-@6.07
0.10 0.09 0.14 0.10
PC 33:3; [M-Ac-H]-@5.84
0.05 0.05 0.05 0.04
PC 34:1; [M-Ac-H]-@6.75
2.80 2.74 2.45 2.51
PC 34:2; [M-Ac-H]-@4.49
0.11 0.15 0.11 0.14
PC 34:2; [M-Ac-H]-@6.31
5.23 4.18 6.10 4.76
PC 34:3; [M-Ac-H]-@5.88
0.39 0.36 0.50 0.33
PC 34:4; [M-Ac-H]-@5.63
2.97 3.27 3.29 2.09
PC 34:5; [M-Ac-H]-@5.24
0.07 0.06 0.08 0.09
PC 35:0; [M-Ac-H]-@7.12
0.04 0.06 0.03 0.05
PC 35:1; [M-Ac-H]-@7.17
0.62 0.52 0.62 0.64
PC 35:2; [M-Ac-H]-@6.69
0.15 0.14 0.19 0.17
PC 35:3; [M-Ac-H]-@6.24
1.32 1.29 1.37 1.66
PC 35:4; [M-Ac-H]-@6.05
0.06 0.04 0.04 0.04
PC 35:5; [M-Ac-H]-@5.60
0.02 0.03 0.02 0.02
PC 36:0; [M-Ac-H]-@7.88
0.09 0.13 0.09 0.10
PC 36:1; [M-Ac-H]-@7.38
2.60 2.86 2.09 1.83
PC 36:2; [M-Ac-H]-@6.94
8.65 7.83 9.40 6.73
PC 36:3; [M-Ac-H]-@6.49
2.01 2.06 2.17 1.89
PC 36:4; [M-Ac-H]-@6.16
6.80 6.17 5.61 4.80
PC 36:4; [M-Ac-H]-@7.52
0.37 0.29 0.47 0.55
PC 36:5; [M-Ac-H]-@5.76
0.34 0.44 0.23 0.24
PC 36:6; [M-Ac-H]-@5.52
0.07 0.09 0.06 0.05
PC 37:1; [M-Ac-H]-@7.67
0.01 0.01 0.01 0.01
PC 37:2; [M-Ac-H]-@7.32
0.10 0.09 0.14 0.06
PC 37:3; [M-Ac-H]-@6.95
0.94 1.42 0.98 1.09
PC 37:4; [M-Ac-H]-@6.72
0.10 0.09 0.07 0.09
PC 37:5; [M-Ac-H]-@6.15
0.02 0.03 0.01 0.02
PC 37:6; [M-Ac-H]-@5.93
0.29 0.31 0.25 0.30
PC 38:1; [M-Ac-H]-@7.90
0.06 0.06 0.06 0.07
PC 38:2; [M-Ac-H]-@7.55
0.18 0.18 0.19 0.15
PC 38:3; [M-Ac-H]-@7.18
0.94 1.21 0.92 0.79
PC 38:4; [M-Ac-H]-@6.83
5.13 5.49 3.28 3.74
PC 38:5; [M-Ac-H]-@6.47
2.21 3.06 1.71 1.79
PC 38:6; [M-Ac-H]-@6.12
0.74 0.82 0.40 0.53
PC 38:7; [M-Ac-H]-@5.63
0.31 0.43 0.28 0.24
PC 39:3; [M-Ac-H]-@7.46
0.17 0.39 0.27 0.17
PC 39:4; [M-Ac-H]-@7.31
0.05 0.07 0.05 0.05
PC 39:5; [M-Ac-H]-@6.71
0.01 0.02 0.01 0.01
PC 39:6; [M-Ac-H]-@6.61
0.03 0.05 0.02 0.04
PC 40:1; [M-Ac-H]-@8.45
0.02 0.03 0.02 0.03
PC 40:2; [M-Ac-H]-@8.20
0.21 0.17 0.42 0.28
PC 40:3; [M-Ac-H]-@7.67
0.07 0.04 0.04 0.04
PC 40:4; [M-Ac-H]-@7.41
0.32 0.38 0.24 0.25
PC 40:5; [M-Ac-H]-@7.13
0.64 0.78 0.32 0.45
PC 40:6; [M-Ac-H]-@6.78
0.39 0.47 0.19 0.33
PC 40:7; [M-Ac-H]-@6.31
0.04 0.04 0.03 0.04
PC 40:8; [M-Ac-H]-@5.88
0.08 0.06 0.08 0.09
PC 40:9; [M-Ac-H]-@5.54
0.10 0.07 0.06 0.06
PC 42:10; [M-Ac-H]-@5.81
0.02 0.03 0.02 0.03
PC 42:2; [M-Ac-H]-@8.73
0.01 0.01 0.02 0.01
PC 42:3; [M-Ac-H]-@8.17
0.02 0.01 0.01 0.02
PC 42:4; [M-Ac-H]-@7.99
0.12 0.07 0.11 0.10
PC 42:5; [M-Ac-H]-@7.55
0.01 0.01 0.01 0.01
PC 44:12; [M-Ac-H]-@5.69
0.00 0.00 0.00 0.00
PC 44:3; [M-Ac-H]-@8.67
0.12 0.13 0.15 0.14
PE 32:0; [M-H]-@6.81
0.10 0.10 0.17 0.12
PE 32:1; [M-H]-@6.32
0.27 0.24 0.49 0.26
PE 33:1; [M-H]-@6.63
0.00 0.00 0.00 0.00
PE 33:2; [M-H]-@6.16
0.00 0.00 0.00 0.00
PE 34:1; [M-H]-@6.92
0.16 0.14 0.21 0.16
PE 34:2; [M-H]-@6.47
0.17 0.12 0.18 0.13
PE 34:3; [M-H]-@6.11
0.02 0.02 0.02 0.01
PE 35:0; [M-H]-@7.65
0.02 0.03 0.01 0.01
PE 35:1; [M-H]-@7.17
0.05 0.10 0.05 0.05
PE 35:2; [M-H]-@6.79
0.02 0.01 0.02 0.02
PE 35:4; [M-H]-@6.14
0.01 0.01 0.01 0.01
PE 36:0; [M-H]-@7.93
0.02 0.02 0.02 0.02
PE 36:1; [M-H]-@6.78
1.45 1.50 1.60 1.55
PE 36:1; [M-H]-@7.50
0.11 0.15 0.11 0.10
PE 36:2; [M-H]-@6.35
0.03 0.02 0.04 0.03
PE 36:2; [M-H]-@7.05
1.36 1.11 1.64 0.96
PE 36:3; [M-H]-@6.60
0.26 0.20 0.41 0.23
PE 36:4; [M-H]-@6.30
10.77 11.11 12.74 11.62
PE 36:5; [M-H]-@6.10
0.03 0.03 0.03 0.02
PE 36:6; [M-H]-@5.66
0.00 0.00 0.00 0.00
PE 37:3; [M-H]-@6.97
0.01 0.00 0.01 0.01
PE 37:4; [M-H]-@6.72
0.08 0.09 0.07 0.09
PE 38:1; [M-H]-@7.41
0.08 0.04 0.07 0.05
PE 38:2; [M-H]-@6.99
0.01 0.01 0.01 0.01
PE 38:2; [M-H]-@7.59
0.02 0.01 0.01 0.01
PE 38:3; [M-H]-@7.30
0.47 0.50 0.51 0.43
PE 38:4; [M-H]-@6.99
1.46 1.43 1.33 1.65
PE 38:5; [M-H]-@6.59
1.35 1.40 1.75 1.29
PE 38:6; [M-H]-@6.23
0.56 0.46 0.41 0.28
PE 39:4; [M-H]-@7.73
0.06 0.05 0.09 0.10
PE 39:5; [M-H]-@6.86
0.33 0.40 0.26 0.48
PE 39:6; [M-H]-@6.61
0.03 0.03 0.03 0.02
PE 40:4; [M-H]-@7.49
0.06 0.06 0.06 0.08
PE 40:5; [M-H]-@7.17
0.40 0.40 0.34 0.33
PE 40:6; [M-H]-@6.97
0.54 0.62 0.34 0.35
PE 40:7; [M-H]-@6.48
0.07 0.06 0.05 0.05
PE 40:8; [M-H]-@6.06
0.02 0.02 0.01 0.02
PG 33:0; [M-H]-@6.13
0.01 0.01 0.01 0.01
PG 33:1; [M-H]-@6.58
0.02 0.02 0.02 0.02
PG 34:2; [M-H]-@5.52
0.00 0.00 0.00 0.00
PG 35:3; [M-H]-@6.36
0.00 0.00 0.00 0.00
PG 36:0; [M-H]-@6.94
0.10 0.15 0.14 0.15
PG 36:1; [M-H]-@6.50
1.12 1.78 1.23 1.16
PG 36:2; [M-H]-@6.15
0.05 0.05 0.05 0.04
PG 38:4; [M-H]-@6.13
0.03 0.03 0.03 0.04
PI 34:1; [M-H]-@5.75
0.03 0.03 0.02 0.01
PI 34:2; [M-H]-@5.33
0.02 0.01 0.02 0.01
PI 36:1; [M-H]-@6.38
0.01 0.01 0.01 0.01
PI 36:2; [M-H]-@5.95
0.05 0.03 0.04 0.02
PI 36:3; [M-H]-@5.45
0.03 0.03 0.03 0.02
PI 36:4; [M-H]-@5.31
0.88 1.07 0.68 0.59
PI 38:3; [M-H]-@6.15
0.17 0.14 0.16 0.13
PI 38:4; [M-H]-@5.95
0.21 0.14 0.12 0.13
PI 38:5; [M-H]-@5.44
0.04 0.04 0.04 0.04
PI 38:6; [M-H]-@5.19
0.02 0.02 0.02 0.01
PI 40:5; [M-H]-@6.20
0.05 0.04 0.04 0.03
PI 40:6; [M-H]-@5.87
0.02 0.02 0.01 0.02
plasmenyl-PE 34:1; [M-H]-@7.24
0.34 0.65 0.29 0.32
plasmenyl-PE 34:2; [M-H]-@6.79
4.37 9.57 7.03 7.12
plasmenyl-PE 34:3; [M-H]-@6.46
0.00 0.01 0.01 0.01
plasmenyl-PE 36:1; [M-H]-@7.80
0.21 0.43 0.28 0.29
plasmenyl-PE 36:2; [M-H]-@7.38
0.59 1.06 1.01 0.59
plasmenyl-PE 36:3; [M-H]-@6.97
0.38 0.58 0.54 0.50
plasmenyl-PE 36:4; [M-H]-@6.72
28.56 53.94 27.27 48.31
plasmenyl-PE 36:5; [M-H]-@6.37
1.99 6.76 1.87 3.08
plasmenyl-PE 38:1; [M-H]-@8.31
0.01 0.01 0.01 0.01
plasmenyl-PE 38:2; [M-H]-@7.95
0.09 0.13 0.15 0.09
plasmenyl-PE 38:3; [M-H]-@7.60
0.21 0.28 0.23 0.27
plasmenyl-PE 38:4; [M-H]-@7.30
1.06 1.39 1.23 1.64
plasmenyl-PE 38:5; [M-H]-@6.84
1.52 2.31 1.56 2.01
plasmenyl-PE 38:6; [M-H]-@6.64
2.00 2.92 2.12 2.05
plasmenyl-PE 40:3; [M-H]-@8.13
0.17 0.20 0.15 0.21
plasmenyl-PE 40:4; [M-H]-@7.82
0.25 0.31 0.32 0.45
plasmenyl-PE 40:5; [M-H]-@7.39
0.23 0.30 0.27 0.31
plasmenyl-PE 40:5; [M-H]-@7.62
0.23 0.30 0.27 0.31
plasmenyl-PE 40:6; [M-H]-@7.21
0.62 0.91 0.66 0.81
plasmenyl-PE 42:4; [M-H]-@8.27
0.07 0.06 0.05 0.06
plasmenyl-PE 42:5; [M-H]-@7.94
0.12 0.15 0.11 0.18
plasmenyl-PE 42:6; [M-H]-@7.82
0.05 0.06 0.05 0.08
PS 36:1; [M-H]-@6.46
0.03 0.03 0.02 0.04
PS 38:4; [M-H]-@6.06
0.02 0.02 0.02 0.04
PS 38:5; [M-H]-@5.53
0.00 0.00 0.00 0.00

Factors:

F1diagnosis:BP | gender:F
F2diagnosis:BP | gender:M
F3diagnosis:BP! | gender:M
F4diagnosis:BPI | gender:F
F5diagnosis:BPI | gender:M
F6diagnosis:BPL | gender:M
F7diagnosis:HC | gender:F
F8diagnosis:HC | gender:M
  logo